Self-Assembling Peptide-Adjuvant Nanoparticles Induce Anti-Cancer T Cells Against 50% of Tested Neoantigens
Peptide-TLR-7/8a conjugates that self-assemble into uniform 20nm nanoparticles induced CD8 T cells against ~50% of predicted tumor neoantigens and enhanced tumor clearance in three mouse models.
Quick Facts
What This Study Found
SNP-7/8a self-assembled nanoparticles induced CD8 T cells against ~50% of high-affinity predicted neoantigens (179 tested) and enhanced tumor clearance in three mouse models, with immunogenicity confirmed in primates.
Key Numbers
~20 nm nanoparticles; 179 neoantigens; ~50% CD8 T cell response rate; enhanced tumor clearance in 3 models; confirmed in NHPs
How They Did This
Peptide-TLR-7/8a conjugate chemistry with charge modification; nanoparticle characterization (~20nm); vaccination in 3 mouse tumor models with 179 predicted neoantigens; CD8 T cell response quantification; tumor clearance; non-human primate immunogenicity study.
Why This Research Matters
This solves the key manufacturing bottleneck for personalized cancer vaccines — one platform that works with any neoantigen — potentially enabling rapid, scalable personalized immunotherapy.
The Bigger Picture
Personalized neoantigen vaccines are one of the most promising frontiers in cancer immunotherapy. A generalizable self-assembling platform could make them practical for widespread clinical use.
What This Study Doesn't Tell Us
Mouse tumor models with artificially implanted tumors; ~50% immunogenicity means half of predicted neoantigens didn't work; primate study used mock neoantigens, not real tumor antigens; human clinical data needed.
Questions This Raises
- ?Can the ~50% response rate be improved by better neoantigen prediction algorithms?
- ?How does SNP-7/8a compare to mRNA neoantigen vaccines (like BioNTech/Moderna approaches)?
- ?What is the manufacturing timeline for a patient-specific SNP-7/8a vaccine?
Trust & Context
- Key Stat:
- ~50% neoantigen hit rate CD8 T cells induced against roughly half of 179 high-affinity predicted neoantigens across 3 tumor models
- Evidence Grade:
- High — multi-model animal study with large neoantigen panel (179), primate validation, and tumor clearance demonstrated.
- Study Age:
- Published in 2020; personalized cancer vaccine platforms have continued to advance toward clinical trials.
- Original Title:
- Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.
- Published In:
- Nature biotechnology, 38(3), 320-332 (2020)
- Authors:
- Lynn, Geoffrey M, Sedlik, Christine, Baharom, Faezzah, Zhu, Yaling, Ramirez-Valdez, Ramiro A, Coble, Vincent L, Tobin, Kennedy, Nichols, Sarah R, Itzkowitz, Yaakov, Zaidi, Neeha, Gammon, Joshua M, Blobel, Nicolas J, Denizeau, Jordan, de la Rochere, Philippe, Francica, Brian J, Decker, Brennan, Maciejewski, Mateusz, Cheung, Justin, Yamane, Hidehiro, Smelkinson, Margery G, Francica, Joseph R, Laga, Richard, Bernstock, Joshua D, Seymour, Leonard W, Drake, Charles G, Jewell, Christopher M, Lantz, Olivier, Piaggio, Eliane, Ishizuka, Andrew S, Seder, Robert A
- Database ID:
- RPEP-04974
Evidence Hierarchy
Frequently Asked Questions
What are neoantigens?
Unique mutated proteins found only in a patient's tumor. The immune system can learn to recognize and attack cells displaying these proteins, but needs a vaccine to kickstart the response.
Why do the nanoparticles need to self-assemble?
Each patient's tumor has different neoantigens with different chemical properties. Self-assembly means the same manufacturing process works regardless of which peptides are loaded — critical for personalized medicine.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04974APA
Lynn, Geoffrey M; Sedlik, Christine; Baharom, Faezzah; Zhu, Yaling; Ramirez-Valdez, Ramiro A; Coble, Vincent L; Tobin, Kennedy; Nichols, Sarah R; Itzkowitz, Yaakov; Zaidi, Neeha; Gammon, Joshua M; Blobel, Nicolas J; Denizeau, Jordan; de la Rochere, Philippe; Francica, Brian J; Decker, Brennan; Maciejewski, Mateusz; Cheung, Justin; Yamane, Hidehiro; Smelkinson, Margery G; Francica, Joseph R; Laga, Richard; Bernstock, Joshua D; Seymour, Leonard W; Drake, Charles G; Jewell, Christopher M; Lantz, Olivier; Piaggio, Eliane; Ishizuka, Andrew S; Seder, Robert A. (2020). Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.. Nature biotechnology, 38(3), 320-332. https://doi.org/10.1038/s41587-019-0390-x
MLA
Lynn, Geoffrey M, et al. "Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.." Nature biotechnology, 2020. https://doi.org/10.1038/s41587-019-0390-x
RethinkPeptides
RethinkPeptides Research Database. "Peptide-TLR-7/8a conjugate vaccines chemically programmed fo..." RPEP-04974. Retrieved from https://rethinkpeptides.com/research/lynn-2020-peptidetlr78a-conjugate-vaccines-chemically
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.